Biocept (BIOC) Peer Comparison
$0.07
$0.04
(125.16%)
As on 26-Dec-2023 09:30EDT
Market cap
$1 Mln
Revenue (TTM)
$-14 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Edit
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1 | 12,753 | 12,153 | 10,906 | 9,948 |
Revenue ($ Mln) |
-14 | 1,505 | 6,164 | 613 | 785 |
Net Profit ($ Mln) |
-46.19 | 160.59 | 625.00 | -188.05 | 41.54 |
Net Margin (%) |
320.88 | 10.67 | 5.41 | -30.68 | 5.29 |
RoE (%) |
-1,009.57 | 10.86 | 11.84 | -28.10 | 1.97 |
Price to Earnings |
-- | 79.35 | 19.89 | -- | 251.81 |
Price-To-Book |
0.37 | 8.41 | 2.37 | 16.38 | 4.86 |
Income Statement ($ Mln)
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
-14.39 | 847.13 | 5,215.00 | 282.86 | 801.54 |
|
Cost of Revenue
|
16.94 | 311.93 | 1,515.00 | 68.98 | 345.83 |
|
Gross Profit
|
-2.58 | 535.21 | 3,700.00 | 213.88 | 455.71 |
|
Operating Expenses
|
21.87 | 529.13 | 3,250.00 | 296.20 | 231.04 |
|
Operating Profit (EBIT)
|
-48.90 | 6.08 | 450.00 | -82.31 | 224.67 |
|
Other Income
|
0.00 | -2.33 | -- | 2.38 | -4.37 |
|
Profit before Tax
|
-46.47 | 3.89 | 235.00 | -98.43 | 219.14 |
|
Provision for Tax
|
-0.02 | 5.89 | 12.00 | 0.77 | 33.18 |
|
Profit after Tax (Net Income)
|
-46.19 | -2.00 | 223.00 | -99.20 | 185.96 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-12.69 | -2.00 | 223.00 | -99.20 | 185.96 |
Liabilities ($ Mln)
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
0.29 | 998.86 | 5,259.00 | 530.01 | 1,910.70 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
16.91 | 227.10 | 2,992.00 | 471.80 | 216.70 |
|
Current Liabilities
|
4.90 | 144.93 | 1,715.00 | 72.36 | 404.20 |
|
Total Liabilities
|
30.87 | 1,370.89 | 9,966.00 | 1,074.17 | 2,531.60 |
Assets ($ Mln)
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
13.24 | 615.19 | 6,110.00 | 630.31 | 1,533.48 |
|
Current Assets
|
8.86 | 755.70 | 3,856.00 | 443.86 | 998.12 |
|
Total Assets
|
30.87 | 1,370.89 | 9,966.00 | 1,074.17 | 2,531.60 |
|
Total Debt*
|
11.59 | 235.77 | 2,872.00 | 382.91 | 422.96 |
|
Net Current Assets
|
3.96 | 610.77 | 2,141.00 | 371.50 | 593.92 |
Cashflow ($ Mln)
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-13.29 | -55.66 | 468.00 | -33.08 | 172.08 |
|
Cash Flow from Investing Activities
|
-- | 54.79 | -472.00 | 44.78 | -233.24 |
|
Cash from Financing Activities
|
-1.87 | 11.62 | -926.00 | 6.25 | -13.34 |
|
Net Cash Inflow / Outflow
|
-- | 10.75 | -- | 17.95 | -74.49 |
Ratios
Profitability Ratios
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-90.23 | -0.17 | 2.62 | -10.53 | 8.36 |
|
ROE (%)
|
-1,009.57 | -0.21 | 4.12 | -17.76 | 10.16 |
|
ROA (%)
|
-97.48 | -0.15 | 2.14 | -9.01 | 7.61 |
|
EBIT Margin (%)
|
209.83 | -- | -- | -- | -- |
|
Net Margin (%)
|
320.88 | -0.24 | 4.28 | -34.78 | 23.33 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-125.69 | 0.13 | 0.00 | -0.04 | 0.20 |
|
EBIT Growth (%)
|
-185.16 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-290.80 | -176.32 | -57.44 | -100.02 | 44.95 |
|
EPS Growth (%)
|
-19.85 | -1.73 | -0.57 | -0.97 | 0.47 |
|
Book Value Growth (%)
|
-85.41 | -- | -- | -- | -- |
Valuation Ratios
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.28 | -4,322.18 | 104.88 | -21.02 | 51.99 |
|
Price / Book Value
|
1.02 | 8.66 | 4.45 | 3.93 | 5.06 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.27 | 290.39 | 22.53 | -43.38 | 34.14 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.24 | 0.55 | 0.72 | 0.22 |
|
Short term debt to equity ratio
|
6.57 | 0.01 | 0.03 | 0.00 | 0.15 |
|
Current Ratio
|
1.81 | 5.21 | 2.25 | 6.13 | 2.47 |
|
Quick Ratio
|
1.70 | 2.91 | 0.96 | 5.61 | 1.88 |
|
Interest Coverage
|
-236.09 | 3.23 | 8.23 | -6.17 | 74.00 |
Operating Efficiency Ratios
| Biocept (BIOC) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-5.56 | 24.01 | 19.69 | 12.75 | 14.50 |
|
Asset Turnover
|
-0.30 | 0.65 | 0.50 | 0.26 | 0.33 |
|
Receivable days
|
112.56 | 72.72 | 69.97 | 44.88 | 53.24 |
|
Inventory Days
|
21.88 | 349.83 | 488.08 | 161.11 | 223.26 |
|
Payable days
|
56.31 | 23.48 | 249.77 | 57.55 | 33.67 |
|
Cash Conversion Cycle
|
78.13 | 399.07 | 308.28 | 148.44 | 242.83 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
